These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 10792273)

  • 1. Flow cytometric assessment of CD15+CD117+ cells for the detection of minimal residual disease in adult acute myeloid leukaemia.
    Nakamura K; Ogata K; An E; Dan K
    Br J Haematol; 2000 Mar; 108(4):710-6. PubMed ID: 10792273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunophenotype of c-kit cells in normal human bone marrow: implications for the detection of minimal residual disease in AML.
    Macedo A; Orfao A; Martínez A; Vidriales MB; Valverde B; López-Berges MC; San Miguel JF
    Br J Haematol; 1995 Feb; 89(2):338-41. PubMed ID: 7532985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of cell heterogeneity and immunophenotypic changes on monitoring minimal residual disease in acute myeloid leukemia.
    Zelezníková T; Babusíková O
    Neoplasma; 2006; 53(6):500-6. PubMed ID: 17167719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD117 (c-kit) is a restricted antigen of acute myeloid leukemia and characterizes early differentiative levels of M5 FAB subtype.
    Cascavilla N; Musto P; D'Arena G; Melillo L; Carella AM; Petrilli MP; Sanpaolo G; Carotenuto M
    Haematologica; 1998 May; 83(5):392-7. PubMed ID: 9658721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Analysis of immunophenotype and leukemia associated immunophenotype in 610 patients with acute myeloid leukemia].
    Liu YR; Wang YZ; Chen SS; Chang Y; Fu JY; Li LD; Wang H; Yu H; Jiang B; Huang XJ
    Zhonghua Xue Ye Xue Za Zhi; 2007 Nov; 28(11):731-6. PubMed ID: 18457262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Immunologic characteristics and prognosis of acute myeloid leukemia M1].
    Zhao F; Chen Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Aug; 15(4):687-91. PubMed ID: 17708783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunophenotypic differences between diagnosis and relapse in childhood AML: Implications for MRD monitoring.
    Langebrake C; Brinkmann I; Teigler-Schlegel A; Creutzig U; Griesinger F; Puhlmann U; Reinhardt D
    Cytometry B Clin Cytom; 2005 Jan; 63(1):1-9. PubMed ID: 15624201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of bone marrow specimens with acute myelogenous leukemia for CD34, CD15, CD117, and myeloperoxidase.
    Dunphy CH; Polski JM; Evans HL; Gardner LJ
    Arch Pathol Lab Med; 2001 Aug; 125(8):1063-9. PubMed ID: 11473459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. hMICL and CD123 in combination with a CD45/CD34/CD117 backbone - a universal marker combination for the detection of minimal residual disease in acute myeloid leukaemia.
    Roug AS; Larsen HØ; Nederby L; Just T; Brown G; Nyvold CG; Ommen HB; Hokland P
    Br J Haematol; 2014 Jan; 164(2):212-22. PubMed ID: 24152218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased myeloid precursors in regenerating bone marrow; implications for detection of minimal residual disease in acute myeloid leukemia.
    Zeleznikova T; Stevulova L; Kovarikova A; Babusikova O
    Neoplasma; 2007; 54(6):471-7. PubMed ID: 17949229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD34+CD38-CD123+ Cells Are Present in Virtually All Acute Myeloid Leukaemia Blasts: A Promising Single Unique Phenotype for Minimal Residual Disease Detection.
    Al-Mawali A; Pinto AD; Al-Zadjali S
    Acta Haematol; 2017; 138(3):175-181. PubMed ID: 29065396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study.
    Terwijn M; van Putten WL; Kelder A; van der Velden VH; Brooimans RA; Pabst T; Maertens J; Boeckx N; de Greef GE; Valk PJ; Preijers FW; Huijgens PC; Dräger AM; Schanz U; Jongen-Lavrecic M; Biemond BJ; Passweg JR; van Gelder M; Wijermans P; Graux C; Bargetzi M; Legdeur MC; Kuball J; de Weerdt O; Chalandon Y; Hess U; Verdonck LF; Gratama JW; Oussoren YJ; Scholten WJ; Slomp J; Snel AN; Vekemans MC; Löwenberg B; Ossenkoppele GJ; Schuurhuis GJ
    J Clin Oncol; 2013 Nov; 31(31):3889-97. PubMed ID: 24062400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients.
    San Miguel JF; Martínez A; Macedo A; Vidriales MB; López-Berges C; González M; Caballero D; García-Marcos MA; Ramos F; Fernández-Calvo J; Calmuntia MJ; Diaz-Mediavilla J; Orfao A
    Blood; 1997 Sep; 90(6):2465-70. PubMed ID: 9310499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prognosticating relapse risk based on multiparameter flow cytometric assessment of minimal residual disease in patients with acute myeloid leukemia].
    Wan SG; Zhao H; Sun XJ; He JJ; Su L; Xu J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):557-62. PubMed ID: 19549363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluorescence in situ hybridization in combination with morphology detects minimal residual disease in remission and heralds relapse in acute leukaemia.
    Bernell P; Arvidsson I; Jacobsson B; Hast R
    Br J Haematol; 1996 Dec; 95(4):666-72. PubMed ID: 8982043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flow cytometric assessment of autologous gammadelta T cells in patients with acute myeloid leukemia: potential effector cells for immunotherapy?
    Aswald JM; Wang XH; Aswald S; Lutynski A; Minden MD; Messner HA; Keating A
    Cytometry B Clin Cytom; 2006 Nov; 70(6):379-90. PubMed ID: 16977635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Detection of residual leukemic cells after complete remission of patients with acute myeloid leukemia].
    Xu YL; Zhang XZ; Zhang L; Zhang XQ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2004 Dec; 12(6):858-60. PubMed ID: 15631679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunological evaluation of minimal residual disease (MRD) in acute myeloid leukaemia (AML).
    San-Miguel JF; Vidriales MB; Orfão A
    Best Pract Res Clin Haematol; 2002 Mar; 15(1):105-18. PubMed ID: 11987919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Predictable recurrence by regular monitoring minimal residual disease with flow cytometry in the patients with both AML and ALL: a single-center study of 163 cases].
    Tong CR; Wang H; Yang JF; Lin YH; Zhang X; Zhao J; Fei XH; Gu JY; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2011 Nov; 32(11):748-51. PubMed ID: 22339910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunophenotyping of AML and MDS and detection of residual disease.
    Sanz MA; Sempere A
    Baillieres Clin Haematol; 1996 Mar; 9(1):35-55. PubMed ID: 8730550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.